Virios Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gregory Duncan
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 44 Milton Avenue Alpharetta GA United States of America 30009
- IPO Date
- Dec 17, 2020
- CIK
- 0001818844
- Website
- virios.com
- Similar Companies
- Business
- Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is a development-stage biotechnology company focused on advancing innovative therapies for chronic diseases stemming from viral-triggered abnormal immune responses, and for neuropathic pain. The company's pipeline includes IMC-1, a combination of famciclovir and celecoxib, which is poised for Phase 3 development to address fibromyalgia, having received FDA Fast Track designation. Additionally, the company is progressing IMC-2, a combination of valacyclovir and celecoxib, currently in Phase 2 development, aiming to manage a range of debilitating symptoms associated with Long-COVID, with top-line Phase 2a results anticipated in early Q4 2024. The company also features Halneuron®, a non-opioid therapy in Phase 2b development for chemotherapy-induced neuropathic pain. This strategic entity was formed through a business combination with Wex Pharmaceuticals, Inc., effective October 9, 2024, at which point its common stock began trading under the ticker symbol DWTX on the Nasdaq Capital Market, following a 25-for-1 reverse stock split. Dogwood Therapeutics, Inc. continues operations from Alpharetta, Georgia.
Analyzing Virios Therapeutics (NASDAQ:VIRI) & Palatin Technologies (PINK:PTNT)
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
Virios Therapeutics Announces Second Quarter 2024 Financial Results
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
US Stocks Mixed; Li Auto Shares Plummet After Q1 Results
Why Is Virios Therapeutics (VIRI) Stock Down 44% Today?
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
Virios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call Transcript
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update